7 active not recruiting, 4 completed, 2 recruiting, 1 terminated. 14 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Active not recruiting 7, Completed 4, Recruiting 2, Terminated 1 |
| Phase 2 | 4 | Active not recruiting 3, Completed 1 |
Follow M3814: new trials by email Literature Review of M3814 trials Research Report on M3814
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 66 | 2024-06-07 | 2026-08-24 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-11-04 |
| Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Intensity-Modulated Radiation Therapy, Peposertib - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2021-12-20 | 2026-10-13 |
| Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Neuroendocrine Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-07-22 | 2026-06-15 |
| Effect of Food on Peposertib PK Peposertib - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 12 | 2021-01-14 | 2026-11-06 |
| Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 92 | 2021-01-11 | 2026-11-05 |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Avelumab, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2020-10-14 | 2026-10-07 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2020-05-05 | 2026-06-11 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 103 | 2020-04-07 | 2026-10-02 |
| Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer Peposertib 50 mg, Peposertib 100 mg, Peposertib 150 mg - Locally Advanced Rectal Cancer | Phase 1 / Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 19 | 2019-03-20 | 2023-03-21 |
| Study of Avelumab-M3814 Combinations M3814, Avelumab, Radiotherapy - Oncology, Solid Tumors | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 57 | 2018-11-27 | 2025-04-10 |
| Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) M3814, Cisplatin, Etoposide - Small Cell Lung Cancer | Phase 1 | Terminated | EMD Serono Research & Development Institute, Inc. | 2 | 2017-05-25 | 2020-09-16 |
| Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia MSC2490484A (M3814) - Advanced Solid Tumors, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 31 | 2014-12-31 | 2020-04-28 |
Neoplasm Metastasis (2) · Neoplasms (2) · Carcinoma (1) · Cholangiocarcinoma (1) · Dermatofibrosarcoma (1) · Fallopian Tube Neoplasms (1) · Gallbladder Neoplasms (1) · Histiocytoma, Malignant Fibrous (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Leiomyosarcoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Liposarcoma (1) · Lymphatic Metastasis (1)
National Cancer Institute (NCI) (9) · EMD Serono Research & Development Institute, Inc. (3) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Merck KGaA, Darmstadt, Germany (1)
United States (12) · Belgium (2) · Denmark (2) · Germany (2) · Spain (2) · Bulgaria (1) · Canada (1) · Czechia (1) · Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · Romania (1) · United Kingdom (1)
Brian A Jonas (1) · Candace L Haddox (1) · Gregory M Cote (1) · Kristen R Spencer (1) · Lowell B Anthony (1) · Maura L Gillison (1) · Rachel N Grisham (1) · Russell K Pachynski (1) · Sarah L Davis (1)
UM1CA186691 (2), UM1CA186709 (2), 2014 (1), 2018 (1), U10CA180868 (1), UM1CA186644 (1), UM1CA186689 (1), UM1CA186704 (1), UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1)